The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Intraocular pressure after intravitreal injection of triamcinolone acetonide
Open accessAbstract
AIM: To investigate the intraocular pressure (IOP) response after intravitreal injections of triamcinolone acetonide as treatment of intraocular neovascular or oedematous diseases. METHODS: The prospective consecutive non-comparative interventional case series study included 71 patients (75 eyes) with progressive exudative age related macular degeneration (n = 64 eyes) or diffuse diabetic macular oedema (n = 11 eyes), who received an intravitreal injection of 25 mg triamcinolone acetonide. Mean follow up time was 6.86 (SD 2.52) months (range 3.1-14.47 months). RESULTS: IOP increased significantly (p<0.001) from 15.43 (3.26) mm Hg preoperatively to a mean maximum of 23.38 (8.37) mm Hg (range 13-64 mm Hg) postoperatively. An IOP rise to values higher than 21 mm Hg was observed in 39 (52%) eyes. Elevation of IOP occurred about 2 months after the injection. Preoperative predictive factor for the rise in IOP was younger age (p=0.013). It was statistically independent of refractive error, presence of diabetes mellitus, and indication for the injection. In all but one eye, IOP could be lowered to the normal range with topical medication, without development of glaucomatous optic nerve head changes. In the eyes with an elevation of IOP, IOP normalised about 6 months after the injection, without further medication. Eyes undergoing repeatedly intravitreal injections of triamcinolone acetonide showed only an elevation of IOP, if after the first injection a rise of IOP had occurred. CONCLUSIONS: After intravitreal injections of 25 mg of triamcinolone acetonide, an IOP elevation can develop in about 50% of eyes, starting about 1-2 months after the injection. In the vast majority, IOP can be normalised by topical medication, and returns to normal values without further medication about 6 months after the injection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intravitreal triamcinolone for refractory diabetic macular edema
Martidis, A., Duker, J. S., Greenberg, P. B., Rogers, A. H., Puliafito, C. A., Reichel, E., & Baumal, C. (2002) · Ophthalmology · doi:10.1016/s0161-6420(02)00975-2 · Cited by 1,032
Ophthalmoscopic Evaluation of the Optic Nerve Head
Jonas, J. B., Budde, W. M., & Panda-Jonas, S. (1999) · Survey of Ophthalmology · doi:10.1016/s0039-6257(98)00049-6 · Cited by 607
Self-citationIntravitreal triamcinolone acetonide for exudative age related macular degeneration
Jonas, J. B. (2003) · British Journal of Ophthalmology · doi:10.1136/bjo.87.4.462 · Cited by 492
Self-citationIntravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study
Antcliff, R. J., Spalton, D. J., Stanford, M. R., Graham, E. M., ffytche, T. J., & Marshall, J. (2001) · Ophthalmology · doi:10.1016/s0161-6420(00)00658-8 · Cited by 487
Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema
Jonas, J. B., & Söfker, A. (2001) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(01)01010-8 · Cited by 481
Self-citationINTRAVITREAL TRIAMCINOLONE ACETONIDE IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION
DANIS, R. P., CIULLA, T. A., & PRATT, W. A. (2000) · Retina · doi:10.1097/00006982-200003000-00004 · Cited by 423
Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion
Greenberg, P. B. (2002) · British Journal of Ophthalmology · doi:10.1136/bjo.86.2.247 · Cited by 370
Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis
Young, S., Larkin, G., Branley, M., & Lightman, S. (2001) · Clinical & Experimental Ophthalmology · doi:10.1046/j.1442-9071.2001.00360.x · Cited by 352
Treatment of Intraocular Proliferation with Intravitreal Injection of Triamcinolone Acetonide
Tano, Y., Chandler, D., & Machemer, R. (1980) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)75196-7 · Cited by 338
Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up
Challa, J. K., Gillies, M. C., Penfold, P. L., Gyory, J. F., Hunyor, A. B., & Billson, F. A. (1998) · Australian and New Zealand Journal of Ophthalmology · doi:10.1111/j.1442-9071.1998.tb01330.x · Cited by 324
The Lack of Toxicity of Intravitreally Administered Triamcinolone Acetonide
McCuen, B. W., Bessler, M., Tano, Y., Chandler, D., & Machemer, R. (1981) · American Journal of Ophthalmology · doi:10.1016/0002-9394(81)90013-1 · Cited by 262
Intravitreal triamcinolone and elevated intraocular pressure
Fracs, R. J. B. W., & Fracs, P. E. B. (1999) · Australian and New Zealand Journal of Ophthalmology · doi:10.1046/j.1440-1606.1999.00238.x · Cited by 245
Jonas, J. B., Hayler, J. K., Söfker, A., & Panda-Jonas, S. (2001) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(00)00882-5 · Cited by 241
Self-citationFluocinolone acetonide sustained drug delivery device to treat severe uveitis
Jaffe, G. J., Ben-nun, J., Guo, H., Dunn, J. P., & Ashton, P. (2000) · Ophthalmology · doi:10.1016/s0161-6420(00)00466-8 · Cited by 234
Kwak, H. W. (1992) · Archives of Ophthalmology · doi:10.1001/archopht.1992.01080140115038 · Cited by 228
Exudative macular degeneration and intravitreal triamcinolone A pilot study
Penfold, P. L., Gyory, J. F., Hunyor, A. B., & Billson, F. A. (1995) · Australian and New Zealand Journal of Ophthalmology · doi:10.1111/j.1442-9071.1995.tb00179.x · Cited by 221
Intravitreal Injection of Dexamethasone: Treatment of Experimentally Induced Endophthalmitis
Graham, R. O. (1974) · Archives of Ophthalmology · doi:10.1001/archopht.1974.01010010155016 · Cited by 217
Hida, T., Chandler, D., Arena, J. E., & Machemer, R. (1986) · American Journal of Ophthalmology · doi:10.1016/0002-9394(86)90593-3 · Cited by 217
Inhibition of Intraocular Proliferations with Intravitreal Corticosteriods
Tano, Y., Sugita, G., Abrams, G., & Machemer, R. (1980) · American Journal of Ophthalmology · doi:10.1016/0002-9394(80)90239-1 · Cited by 213
The Clearance of Intravitreal Triamcinolone Acetonide
Schindler, R. H., Chandler, D., Thresher, R., & Machemer, R. (1982) · American Journal of Ophthalmology · doi:10.1016/0002-9394(82)90130-1 · Cited by 209
Jonas, J. B. (2000) · British Journal of Ophthalmology · doi:10.1136/bjo.84.9.1064 · Cited by 193
Self-citationIshibashi, T., Miki, K., Sorgente, N., Patterson, R., & Ryan, S. J. (1985) · Archives of Ophthalmology · doi:10.1001/archopht.1985.01050050100026 · Cited by 190
Ciulla, T. A. (2001) · Archives of Ophthalmology · doi:10.1001/archopht.119.3.399 · Cited by 182
Penfold, P. L., Wen, L., Madigan, M. C., Gillies, M. C., King, N. J. C., & Provis, J. M. (2001) · Clinical and Experimental Immunology · doi:10.1046/j.1365-2249.2000.01316.x · Cited by 167
Penn, J. S., Rajaratnam, V. S., Collier, R. J., & Clark, A. F. (2001) · PubMed · Cited by 159
Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device.
Jaffe, G. J., Yang, C., Guo, H., et al. (2000) · PubMed · Cited by 149
Danis, R. P., Bingaman, D. P., Yang, Y., & Ladd, B. S. (1996) · Ophthalmology · doi:10.1016/s0161-6420(96)30383-7 · Cited by 146
Ranson, N. (2002) · British Journal of Ophthalmology · doi:10.1136/bjo.86.5.527 · Cited by 111
The effects of intravitreal triamcinolone acetonide on experimental pre-retinal neovascularization
Antoszyk, A. N., Gottlieb, J. L., Machemer, R., & Hatchell, D. L. (1993) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/bf01681698 · Cited by 103
Penfold, P. L., Wong, J. G., Gyory, J., & Billson, F. A. (2001) · Clinical & Experimental Ophthalmology · doi:10.1046/j.1442-9071.2001.00407.x · Cited by 97
Retinal Toxicity of Triamcinolone Acetonide in Silicone-Filled Eyes
Kivilcim, M., Peyman, G. A., El-Dessouky, E. S., Kazi, A. A., Cheema, R., & Hegazy, H. M. (2000) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/1542-8877-20001101-07 · Cited by 78
Intraocular Pressure and Its Response to Topical Corticosteroids in Diabetes
BECKER, B. A., Bresnick, G. H., Chevrette, L., et al. (1966) · Archives of Ophthalmology · doi:10.1001/archopht.1966.03850010479003 · Cited by 72
Berger, A., Cheng, C.-K., Pearson, P. A., Ashton, P., Crooks, P. A., Cynkowski, T., Cynkowska, G., & Jaffe, G. J. (1996) · PubMed · Cited by 67
Cited by
Intravitreal Injection of Triamcinolone for Diffuse Diabetic Macular Edema
Jonas, J. B. (2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.1.57 · Cited by 563
Self-citation(2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.06.015 · Cited by 548
Intravitreal triamcinolone acetonide for exudative age related macular degeneration
Jonas, J. B. (2003) · British Journal of Ophthalmology · doi:10.1136/bjo.87.4.462 · Cited by 492
Self-citationMassin, P., Audren, F., Haouchine, B., Erginay, A., Bergmann, J.-F., Benosman, R., Caulin, C., & Gaudric, A. (2004) · Ophthalmology · doi:10.1016/j.ophtha.2003.05.037 · Cited by 420
Intraocular Pressure Elevation After Intravitreal Triamcinolone Acetonide Injection
JONAS, J., DEGENRING, R., KREISSIG, I., AKKOYUN, I., & KAMPPETER, B. (2005) · Ophthalmology · doi:10.1016/j.ophtha.2004.10.042 · Cited by 323
Self-citation
Metadata
- Authors
- Jonas, J. B.
- Venue
- British Journal of Ophthalmology
- Publisher
- BMJ
- Published
- 2003-01-01
- Volume
- 87
- Issue
- 1
- Pages
- 24-27
- ISSN
- 0007-1161 (ISSN-L)
- OpenAlex
- W1997013893
- Cited by
- 422
- References
- 33
- FWCI
- 51.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.